Skip to main content

Advertisement

Table 1 Summary of subgroup characteristics in 1662 patients

From: Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients

Variables (%) Triple negative ERBB2+ HR+/ERBB2- Pvalue
  n = 321 n = 444 n = 897  
Mean age at diagnosis (year, ± SD) 52.02 ± 10.49 52.12 ± 9.99 53.16 ± 11.56 0.416
Tumor size     
   ≤ 2 cm 139 (43.30) 148 (33.33) 439 (48.94) < 0.001
   >2 cm 182 (56.70) 296 (66.67) 458 (51.06)  
Number of ALNs involved     
   0 190 (59.19) 233 (52.48) 538 (59.98)  
   1-3 72 (22.43) 107 (24.10) 214 (23.86) 0.020
   ≥ 4 59 (18.38) 104 (23.42) 145 (16.16)  
Histological grade     
   I/II 151(61.56) 237 (74.29) 499 (81.80) 0.002
   III 60 (28.44) 82 (25.71) 111 (18.20)  
   Not known 110 126 287  
Systemic treatment     
   Yes 302 (94.08) 426 (95.95) 852 (94.98) 0.494
   No 19 (5.92) 18 (4.05) 45 (5.02)  
All relapse     
   Yes 51 (15.79) 65 (14.64) 79 (8.81) < 0.001
   No 270 (84.11) 379 (85.36) 818 (91.19)  
Locoregional relapse     
   Yes 25 (7.79) 35 (7.79) 35 (3.90) 0.003
   No 296 (92.21) 409 (92.12) 862 (96.10)  
   Mean TTE (years) 2.19 2.03 2.02 ------
Visceral relapse     
   Yes 15 (4.67) 25 (5.63) 23 (2.56) 0.014
   No 306 (95.33) 419 (94.37) 874 (97.44)  
   Mean TTE (years) 1.64 2.02 2.49 ------
Bone relapse     
   Yes 12 (3.74) 7 (1.58) 16 (1.78) 0.074
   No 309 (96.26) 437 (98.42) 881 (98.22)  
   Mean TTE (years) 3.04 2.24 2.57 ------
  1. Abbreviations: HR = hormone receptor; SD = standard deviation; ALNs = axillary lymph nodes; TTE = time to event